Home › Research › Down syndrome and Alzheimer's
The effects of mosaicism on biological and clinical markers of Alzheimer's disease in adults with Down syndrome
Xicota L, Dang LT, Lee A, Krinsky-McHale S, Pang D, Melilli L, O'Bryant S, Henson RL et al.. EBioMedicine, 2024-11-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Individuals with Down syndrome (DS) are at high risk of early-onset Alzheimer's disease (AD); yet, some 20 percent do not develop any signs of dementia until after 65 years or in their lifetime. Mosaicism could contribute to this phenotypic variation, where some disomic cells could lead to lower levels of gene products from chromosome 21. Methods We examined longitudinal neuropsychological and biomarker data from two large studies of DS: the Alzheimer Biomarker Consortium-Down syndrome study (ABC-DS) (n = 357); and a legacy study (n = 468). We assessed mosaicism using karyotyping or GWAS data. Participants had data on plasma AD biomarkers (Aβ 40 , Aβ 42 , tau, and NfL) and longitudinal cognitive measures. A subset had cerebrospinal fluid biomarkers (Aβ 40 , Aβ 42 , tau, ptau181, and NfL) and amyloid and tau PET data. Findings For both cohorts, the prevalence of mosaicism was 40 and Aβ 42 concentrations. For the older legacy cohort, when compared to those with full trisomy, those with mosaicism had significantly smaller decline in total and annualized neurocognitive scores, and lower incidence and prevalence of dementia. Interpretation Mosaicism in DS was associated with lower concentrations of plasma Aβ peptides, possibly leading to lower AD risk. However, its clinical impact was less clear in the younger ABC-DC cohort, and a follow-up study is warranted. Funding National Institutes of Health (R01AG014673, P01HD035897, R56AG061837), NIA (U01AG051412, U19AG068054), NICHD, ADRC programs, the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers Program, and NCATS (UL1TR001873).
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 357 participants. In an older cohort, adults with Down syndrome who had mosaicism showed less cognitive decline and lower incidence and prevalence of dementia than those with full trisomy. Mosaicism was also linked to lower plasma amyloid peptide concentrations, possibly lowering Alzheimer's risk, but the clinical impact was less clear in the younger cohort and follow-up is needed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Xicota, L., Dang, L. T., Lee, A., Krinsky-McHale, S., Pang, D., Melilli, L., et al. (2024). The effects of mosaicism on biological and clinical markers of Alzheimer's disease in adults with Down syndrome. EBioMedicine. https://doi.org/10.1016/j.ebiom.2024.105433
Vancouver
Xicota L, Dang LT, Lee A, Krinsky-McHale S, Pang D, Melilli L, et al. The effects of mosaicism on biological and clinical markers of Alzheimer's disease in adults with Down syndrome. EBioMedicine. 2024. doi:10.1016/j.ebiom.2024.105433. PMID: 39500037.
BibTeX
@article{xicota2024-39500037,
author = {Xicota, L. and Dang, L. T. and Lee, A. and Krinsky-McHale, S. and Pang, D. and Melilli, L. and O'Bryant, S. and Henson, R. L. and others},
title = {{The effects of mosaicism on biological and clinical markers of Alzheimer's disease in adults with Down syndrome}},
journal = {EBioMedicine},
year = {2024},
doi = {10.1016/j.ebiom.2024.105433},
pmid = {39500037},
url = {https://doi.org/10.1016/j.ebiom.2024.105433}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- For the older legacy cohort, when compared to those with full trisomy, those with mosaicism had significantly smaller decline in total and annualized neurocognitive scores, and lower incidence and prevalence of dementia.
- Interpretation Mosaicism in DS was associated with lower concentrations of plasma Aβ peptides, possibly leading to lower AD risk.
Why it matters
In an older cohort, adults with Down syndrome who had mosaicism showed less cognitive decline and lower incidence and prevalence of dementia than those with full trisomy. Mosaicism was also linked to lower plasma amyloid peptide concentrations, possibly lowering Alzheimer's risk, but the clinical impact was less clear in the younger cohort and follow-up is needed.
Study details
- Study designlongitudinal study
- Participants357
- Evidence strengthModerate
How this study scored 56/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 54 of the 96 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (EBioMedicine) |
| Journal's citation record | 2 / 4 | EBioMedicine: journal h-index 181 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 357 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 2.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39500037) |
| Free to read | 2 / 2 | Free to read |
| Points | 54 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 54 of the 96 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.